Clinical trial NCT05184504: Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Official title: Renal Cell Cancer Registry in Latin American Clinical-phatological Characterization and Outcomes of Renal Cell Carcinoma in Latin America
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Kidney Neoplasms
Lead sponsor: Latin American Cooperative Oncology Group
Sponsor class: OTHER
Collaborators: name: Ipsen
First posted: 2022-01-11
Enrollment: 211
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 18 years or older, who have been diagnosed with renal cell carcinoma (new case or recurrence) since January 2015 and during the study recruitment period.

Brief summary: Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.


Eligibility criteria: Inclusion Criteria:

* Patients ≥ 18 years of age;
* Proven histology of renal cell carcinoma (any subtype);
* Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center;
* Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome.

Exclusion Criteria:

* Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).

Primary outcomes:
measure: Build a real-life renal cell cancer database in Brazil and Latin America
timeFrame: 2022
Secondary outcomes:
measure: Sociodemographic characteristics checklist
timeFrame: 2022
measure: Clinicopathological characteristics of patients with renal cell cancer checklist
timeFrame: 2022
measure: Characteristics of systemic treatment checklist
timeFrame: 2022
measure: Time between diagnosis and start of treatment.
timeFrame: 2022
measure: Causes of delay or discontinuation of each treatment checklist
timeFrame: 2022
measure: Progression-free survival in each therapeutic line
timeFrame: 2022
measure: Overall survival
timeFrame: 2022
Other outcomes:
Locations:
city: Manaus
country: Brazil
facility: CINPAM - Centro Integrado de Pesquisa da Amazônia
state: Amazonas
city: Feira De Santana
country: Brazil
facility: Santa Casa de Misericórdia de Feira de Santana
state: Bahia
city: Salvador
country: Brazil
facility: NOB - Núcleo de Oncologia da Bahia (Oncoclínicas)
state: Bahia
city: Fortaleza
country: Brazil
facility: Oncocentro Ceará (Rede D'or)
state: Ceará
city: Brasília
country: Brazil
facility: Onco-Vida Instituto Especializado de Oncologia
state: Distrito Federal
city: Cachoeiro De Itapemirim
country: Brazil
facility: Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO)
state: Espírito Santo
city: São Luís
country: Brazil
facility: Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho
state: Maranhão
city: Campo Grande
country: Brazil
facility: Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo
state: Mato Grosso Do Sul
city: Curitiba
country: Brazil
facility: ICTR - Instituto do Câncer e Transplante de Curitiba
state: Paraná
city: João Pessoa
country: Brazil
facility: Hospital Napoleão Laureano
state: Paraíba
city: Belém
country: Brazil
facility: Hospital Porto Dias
state: Pará
city: Porto Alegre
country: Brazil
facility: CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS
state: Rio Grande Do Sul
city: Santa Maria
country: Brazil
facility: Clínica de Hematologia e Oncologia Viver
state: Rio Grande Do Sul
city: Rio De Janeiro
country: Brazil
facility: CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)
city: São Paulo
country: Brazil
facility: Hemomed Instituto de Oncologia e Hematologia
city: São Paulo
country: Brazil
facility: CPO - Centro Paulista de Oncologia (Oncoclínicas)
Study officials:
affiliation: Latin American Cooperative Oncology Group
name: André Poisl Fay
role: PRINCIPAL_INVESTIGATOR
References: